Alpha-mannosidosis: 2026 so far

Evidence moved from single cases to small registry observations.

New in the months covered, a small French registry described how people did on velmanase alfa in routine care (everyday clinical practice). Clinicians recorded improvements in motor function and wellbeing, and charted manifestations described as stable or improved at last follow-up. The same report also listed treatment-related side effects in 3 of 16 patients, including one person who stopped after two severe infusion reactions (reactions during or soon after an infusion); treatment-related events were reported as resolved. Earlier in the year’s available reports, a single-child case report over 12 months described improved movement and language with stable hearing and no treatment-related adverse events. This helps set expectations for the kinds of day-to-day changes and infusion-related tolerability issues that have been seen outside standardized trials, while still being based on limited data.

Research covered in: August 2026, September 2026

Animal data suggested benefit in late disease, with a dose ceiling.

In the months covered, the main gene-therapy update was an animal study in late-stage cats, where systemic AAV gene therapy (a virus-based gene delivery approach) was linked to some clinical improvement and longer survival compared with untreated cats. The same study reported that benefits were smaller than when treatment is given earlier, and that higher gene-therapy doses did not improve outcomes in this late-stage setting. Because this evidence is from a feline model rather than patients, it does not establish what would happen in people. Still, it shows that in this late-stage model the benefit was partial, and simply increasing the dose did not add benefit.

Research covered in: May 2026

Biochemical monitoring advanced from concept to a reported test.

New in the months covered, a lab-based urine test measuring oligosaccharide fragments (small sugar-chain pieces) was reported to clearly separate people with alpha-mannosidosis from controls, with little overlap between groups. One marker (GlcNAc(Man)2) also differed between untreated individuals and those who had received enzyme replacement therapy (ERT; regular infusions of a missing enzyme), and between untreated individuals and those who had a stem cell transplant (a procedure that replaces blood-forming cells), suggesting sensitivity to treatment-related biochemical shifts. The report emphasized lab performance characteristics (such as precision and recovery), but did not establish how marker changes relate to symptoms or long-term outcomes. This points to a possible number-based way to support diagnosis and to follow biochemical change before and after major interventions, even though the link to how someone feels or functions is not yet established.

Research covered in: May 2026

Research emphasized more standardized growth and lived-experience measures.

In the months covered, studies focused on making outcomes easier to measure consistently across clinics and studies, rather than comparing treatments. An automated system for reading hand X-rays estimated bone age (how mature the bones look for age) about as well as expert consensus and, in comparisons, better than individual expert readers, though with some outliers and a slight tendency to rate bone age older than consensus. Separately, in a small US caregiver sample reporting on 20 people with alpha-mannosidosis, structured interviews captured disease-specific symptoms and concerns that generic questionnaires did not fully cover, with moderate to strong overlap with a generic health status measure in several areas but less overlap for emotional impacts. These tools could shape what gets tracked in registries and studies (growth and day-to-day functioning), even though they do not yet show that using the tools improves care or outcomes.

Research covered in: February 2026

Clinical reports added detail on delays and progressive eye changes.

In the months covered, reports emphasized that symptoms can begin years before diagnosis is confirmed, and that confirmation often relied on both enzyme testing (measuring enzyme activity) and genetic testing (looking for changes in the MAN2B1 gene) when imaging findings varied. Eye involvement was described in multiple single-patient reports: one long follow-up tracked step-by-step retinal worsening (progressive damage to the light-sensing layer of the eye) over about a decade, and another case report in a teenager linked reduced vision to retinal and optic nerve changes with abnormal dim-light retinal responses but normal bright-light responses. These are descriptive reports and do not establish how common any specific eye pattern is or predict progression for others. They give concrete examples of what clinicians may check for when symptoms or vision changes raise concern, including combined diagnostic testing and detailed eye evaluations.

Research covered in: January 2026, June 2026